Psyence Biomedical Ltd. (NASDAQ: PBM) has released its annual report for the fiscal year ending March 31, 2025. The company reported a substantial increase in sales and marketing expenses, amounting to $483,530, compared to $80,603 in the previous year. This significant rise is attributed to the company's strategic efforts to enhance investor awareness and brand positioning following its NASDAQ listing in January 2024. These efforts included expanded investor relations, participation in conferences and roadshows, and enhancements to promotional materials. The company is focused on developing botanical psilocybin-based psychedelic medicines for mental health disorders, particularly in the context of palliative care. Psyence Biomedical is conducting clinical trials to assess the safety and effectiveness of natural psilocybin in treating adjustment disorder in cancer patients receiving palliative care. No specific figures on revenue, net income, or earnings per share were disclosed in the report. The company has not provided an outlook or guidance for the upcoming fiscal period.